Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Exosomes From Adipose-Derived Stem Cells Inhibit Skin T-Cell Activation and Alleviate Wound Inflammation.

Ding H., Wang Y., Bai R., Li Q., Ren B., Jin J.

Animal Study on Chronic Wound, published in Aesthet Surg J (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Aesthet Surg J (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
40100757
DOI
10.1093/asj/sjaf040
Citations
5

Abstract (original English)

Background Skin T cells are essential for maintaining the skin's immune barrier and promoting early wound healing. Exosomes from adipose-derived stem cells (ADSCs-exo) can accelerate wound healing and reduce inflammation, but their impact on skin T-cell inflammation is unclear. Objectives This study aims to explore ADSCs-exo's regulatory effects on skin T cells and wound inflammation. Methods ADSCs-exo were isolated by differential ultracentrifugation. An in vitro inflammation model using the human skin T-cell line HuT 78 was established to analyze the effects of ADSCs-exo on T-cell activation markers, inflammatory cytokines, and PI3K/Akt signaling. Apoptosis in HuT 78 cells was assessed with Calcein-AM/PI staining. A full-thickness skin injury model in C57 mice was used to evaluate ADSCs-exo's impact on dendritic epidermal T cells (DETCs) and inflammatory cytokine expression. Results Phorbol 12-myristate 13-acetate (PMA) enhanced interleukin (IL)-2, IL-17A, tumor necrosis factor alpha, and interferon gamma mRNA expression elevated T cell activation marker CD25 and reduced Akt/PI3K phosphorylation in HuT 78 cells, while inducing apoptosis. Although ADSCs-exo alone showed no CD25 modulation, their co-administration with PMA attenuated CD25 expression, inhibited IL-2 and IL-17A, and enhanced Akt/PI3K phosphorylation compared with PMA alone. Furthermore, ADSCs-exo can reverse the

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansExosomesSkinWound HealingMiceLymphocyte ActivationMice, Inbred C57BLT-LymphocytesDisease Models, Animal

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research